Trial Profile
Overcoming Endocrine Resistance in Metastatic Breast Cancer: A Randomized Trial With Factorial Design Comparing Fulvestrant +/- Lapatinib +/- Aromatase Inhibitor [exemestane, anastrozole, letrozole] in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Lapatinib (Primary) ; Anastrozole; Exemestane; Letrozole
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms OVER
- 25 Jun 2008 New trial record.